Key Takeaways
- A startup, Ceretas, has licensed promising ultrasound therapy from the University of Queensland to target Alzheimer’s disease.
- The treatment aims to enhance neuronal signaling and remove toxic proteins linked to Alzheimer’s, potentially offering a non-invasive solution.
- The first human safety trial has been completed, with results expected to be published in early 2025.
Innovative Ultrasound Therapy for Alzheimer’s Under Development
Ceretas, a new startup formed from research at the University of Queensland (UQ), is advancing a groundbreaking ultrasound therapy aimed at restoring brain function in individuals with Alzheimer’s disease. This innovative technology, developed by Professor Jürgen Götz at UQ’s Queensland Brain Institute, utilizes focused sound pressure waves to reactivate the brain’s neuronal activity and facilitate the removal of harmful proteins associated with Alzheimer’s.
The therapeutic approach not only enhances communication between brain cells, thereby improving memory and cognitive functions, but it also activates the brain’s innate mechanisms to clear damaging proteins such as amyloid and tau, which accumulate in those with Alzheimer’s. “Therapeutic ultrasound offers a non-invasive way of enhancing cognition,” explained Professor Götz, emphasizing its potential beyond Alzheimer’s to include a range of neurodegenerative diseases, such as frontotemporal dementia, amyotrophic lateral sclerosis, and some mental health disorders.
With the global incidence of dementia projected to reach 82 million by 2030, and Alzheimer’s disease accounting for approximately 80 percent of these cases, the urgent need for effective treatment options is clear. Existing medications primarily focus on managing symptoms rather than providing a cure, highlighting the significance of this promising technology.
The first human clinical safety trial for the novel ultrasound device was successfully concluded in 2024 and was led by Professor Peter Nestor from Queensland Brain Institute. Anticipation builds as the trial results are set to be published in early 2025, providing crucial insights into the therapy’s effectiveness and safety.
Ceretas was formed through the collaboration of UQ’s commercialization company, UniQuest, and early-stage investors Ryan Laws and Sam Wetzler. Laws expressed optimism about the therapeutic ultrasound’s potential, stating, “It’s not often that you see potentially game-changing technology coupled with brilliant people.”
UniQuest CEO Dr. Dean Moss echoed this sentiment, remarking on the gratifying progress of such innovative research into clinical trials with vital investor support. He noted that with an aging population leading to rising instances of neurodegenerative diseases, the quality of UQ research is being recognized, attracting investment directed at developing treatments that can genuinely improve patient outcomes.
Overall, this ultrasound therapy presents a promising avenue for tackling one of the most pressing health challenges of our time, aiming to offer hope to millions affected by Alzheimer’s disease and other neurodegenerative conditions.
The content above is a summary. For more details, see the source article.